Exclusive Summary

• - Originator patents and data exclusivity have largely expired in most markets, making the fixed-combination generic pathway mature and predictable.
• - Large, chronic user base in glaucoma/ocular hypertension (about 76 million patients in 2020, projected >110 million by 2040) sustains steady demand for adherence-friendly fixed combinations.
• - Fixed combo (prostaglandin analog plus beta-blocker) is guideline-endorsed for step-up therapy, delivering an extra ~1–3 mmHg IOP reduction over monotherapy with simpler dosing.
• - Global competition is moderate to high (especially India and emerging markets), but high-quality sterile manufacturing, stability, and robust registration support enable differentiation.
• - Typical 30–70% price discount vs originator supports access in EMEA/LATAM/APAC and drives reimbursement and tender wins.